Radio and PodcastLive Radio & PodcastsLoading episode
Fetching episode details...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & Podcasts
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? is an episode from GRACEcast Lung Cancer Video by cancerGRACE - H. Jack West, MD. The REVEL trial studied 1,200 non-small cell lung cancer pat...
This episode belongs to GRACEcast Lung Cancer Video.
Use the player on this page to stream the episode online.
Published Jul 17, 2014, 07:28 long, audio available.
Continue listening to more episodes from GRACEcast Lung Cancer Video.
Jul 29, 2014 - 01:55
Jul 24, 2014 - 02:03
Jul 20, 2014 - 04:40
Jul 15, 2014 - 03:15
Jul 13, 2014 - 07:22